NewTimeSpace News: IMMUNEONCO-B (01541.HK) announced on 10 July that first patient dosing has been completed in the Phase II/III clinical trial of self-developed IMM0306 for IgG4-related disease (IgG4-RD). IMM0306 is the world’s first CD47/CD20 bispecific molecule to enter clinical development. The Company owns global intellectual property and commercialisation rights for IMM0306, while cautioning there is no guarantee of successful development or eventual launch.
NewTimeSpace News: PEGBIO CO-B (02565.HK) announced on 10 July that it has entered into a memorandum of understanding with Nasdaq-listed Rani Therapeutics Holdings, Inc. The parties intend to leverage Rani’s proprietary RaniPill® oral biologic delivery platform to develop oral formulations for multiple innovative candidates targeting obesity and metabolic disorders, pursuing formulation differentiation based on multi-target metabolic modulators and long-acting pipeline assets. The MOU is valid for three years and non-binding; formal agreements will be executed for specific projects.
NewTimeSpace News: EACON (07687.HK) announced on 9 July that it acted as the second completing entity for the project “Key Technologies and Application of Green, Intelligent, Safe and High-efficiency Mining for Large Open-pit Mines”, which has won the Second Prize of State Scientific and Technological Progress Award. This highest-level national government science and technology award recognises the Company’s technological strengths in mine intelligence and autonomous driving. Relevant technical outcomes align closely with the Group’s core unmanned mining solutions and are expected to lift brand influence and market competitiveness.
NewTimeSpace News: SIMCERE PHARMA (02096.HK) announced on 9 July that its Class 1 innovative drug Xibi Xin® (Edaravone and Dexborneol Concentrated Solution for Injection) has been included in the 2026 National Essential Medicines List for the treatment of acute ischaemic stroke. Already listed in national medical insurance, it is the sole neuroprotective agent recommended with Class IIa evidence in Chinese clinical guidelines and has benefited over 6 million AIS patients. The inclusion will accelerate penetration into grassroots medical markets.
NewTimeSpace News: BAIYUNSHAN PH (00874.HK) announced on 9 July that Dexamethasone Sodium Phosphate Injection (1ml:5mg) manufactured by its controlled subsidiary Tianxin Pharmaceutical has passed the generic drug consistency evaluation. The domestic sales of this specification reached RMB236 million in 2025. The Group invested approximately RMB3.1678 million in relevant R&D. The approval is expected to boost product competitiveness, while uncertainties remain in production and sales.
NewTimeSpace News: Micot Pharma-B (02335.HK) announced on 9 July that the Phase II clinical trial of MT1002, the world’s first dual anticoagulant and antiplatelet peptide candidate, for anticoagulation in haemodialysis patients has completed first patient enrolment. The molecule exerts both anticoagulant and antiplatelet effects, featuring rapid onset and eliminating frequent monitoring requirements.
On July 9, Hong Kong equities surged before retreating, with LLM stocks diverging while semiconductor hardware rallied against the broader market. KNOWLEDGE ATLAS successfully completed a HKD 31.41 billion discounted share placement—setting a record for the largest post-IPO equity financing in the domestic LLM sector—propelling its stock up 11.3%. Conversely, MiniMax plunged 18% as its lock-up period expired. The industry is accelerating toward edge AI and agentic capabilities: StepFun announced plans to launch the world's first native AI agent smartphone ahead of OpenAI and is preparing for a Hong Kong IPO. Meanwhile, Amazon is reportedly advancing a secret Alexa AI project, "Moonraker," though its projected GPU costs exceeding USD 100 million in 2026 have raised internal concerns.
NewTimeSpace News: Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) announced that the Phase III clinical trial (CTR20261818) of self-developed first-in-class multi-target tumour immune modulator C019199 tablets has officially been initiated for osteosarcoma patients who failed at least two prior lines of treatment. Approximately 120 subjects are planned to be recruited across multiple clinical centres nationwide.
NewTimeSpace News: On 9 July 2026, XPENG-W(09868.HK) saw weak performance in the afternoon session. As of 15:03, the stock was quoted at HK$51.05, down 2.11%. XPEV recently officially launched its X-Mind technical framework.
NewTimeSpace (newtimespace.com) reported that on July 9, 2026, the chip concept theme strengthened, with ASMPT(00522.HK) fluctuating higher. As of 13:30, the stock was quoted at HKD 192.000, up 3.73%.
NewTimeSpace (newtimespace.com) reported that on July 9, 2026, the humanoid robot concept continued to decline during trading, with Xiaomi-W (01810.HK) fluctuating lower. As of 13:18, the stock was quoted at HKD 24.640, down 2.61%.
The launch of WebRetriever forms a technical matrix alongside Mano-P, Cider, and Octo. In the first half of 2026, Mininglamp Technology (2718.HK) open-sourced Mano-P, an on-device GUI model (ranking first globally on the dedicated OSWorld model leaderboard), Cider, an inference acceleration framework, and Octo, an Agent collaboration platform. The addition of WebRetriever allows the company to form a complete technical closed loop across four dimensions: "on-device model—inference acceleration—collaboration platform—evaluation standard."
Zhipu AI proposes to place up to 19.78 million new H shares at HK$1,588 each, representing a discount of approximately 12.99% to the closing price, to raise net proceeds of approximately HK$31.375 billion. The proceeds will be used for R&D, computing resource deployment, business expansion and strategic M&A. The placing is expected to complete on 13 July 2026 without requiring further shareholders' approval.
NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that the Phase I clinical trial of HLX05-N, its self-developed cetuximab injection biosimilar, has completed first patient dosing in Chinese Mainland for patients with metastatic colorectal cancer (mCRC). Global sales of cetuximab injection reached approximately USD1.658 billion in 2025 based on IQVIA data. The IND applications for the Phase I trial of HLX05-N were approved by NMPA and the FDA in April and May 2026 respectively. Investors are reminded of uncertainties in drug research and development.
On July 8, Hong Kong stocks rallied strongly, with the AI and LLM supply chains erupting across the board. Alibaba surged over 12% on enterprise agent consolidation, while Kuaishou advanced nearly 9% following Kling AI's financing. Among LLM pure-plays, KNOWLEDGE ATLAS and MiniMax both skyrocketed over 12%, buoyed by long-term holding commitments from key shareholders. The semiconductor and hardware sectors strengthened concurrently, driven by Hua Hong's price target upgrade and Inspur's earnings beat. In industry news, MIIT announced China's core AI industry exceeded RMB 1.2 trillion in 2025; xAI officially rebranded as SpaceXAI post-merger; and Tencent hired former OpenAI researcher Yonglong Tian to bolster VLM development.
NewTimeSpace (newtimespace.com) reported that on July 8, 2026, the chip theme strengthened, with SMIC (00981.HK) surging in volatile trading. As of 13:34, the stock was quoted at HKD 77.550, up 5.58%.
